Showing 2531-2540 of 5693 results for "".
- Norlase Announce the Addition of Distributor Partnershipshttps://modernod.com/news/norlase-announce-the-addition-of-distributor-partnerships/2478690/Norlase announced the addition of distributor partnerships in Eastern Europe, Middle East, Oceania and Southeast Asia. “Following our recent expansion into the broader European countries, we are thrilled to establish distributor relationships in these key markets,” Oliver Hvidt, CEO and Pr
- Nidek Launches B-scan Denoising Software With Deep Learning to Enhance OCT Retinal Image Qualityhttps://modernod.com/news/nidek-launches-b-scan-denoising-software-with-deep-learning-to-enhance-oct-retinal-image-quality/2478684/Nidek has announced the launch of the B-scan Denoising Software for the Nidek OCT series. This software converts a B-scan retinal OCT image to a high definition image by a denoising technique using deep learnin
- Kubota Vision Provides Update on Kubota Glasses—Wearable Device for Myopia Controlhttps://modernod.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/Kubota Vision announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology. Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glass
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseaseshttps://modernod.com/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/2478679/Gyroscope Therapeutics announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope
- Novartis Reports Positive Topline Results From Second Phase 3 Trial of Beovu in Patients With DMEhttps://modernod.com/news/novartis-reports-positive-topline-results-from-second-phase-3-trial-of-beovu-in-patients-with-dme/2478658/Novartis announced positive findings from the first interpretable results of the phase 3 KESTREL study, assessing the efficacy and safety of Beovu (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME). Following KITE, KESTREL is the second pivotal phase 3 study of Beovu in DME. The
- Foundation Fighting Blindness Appoints Peter Ginsberg as Executive Vice President, Corporate Development, Chief Business Officerhttps://modernod.com/news/foundation-fighting-blindness-appoints-peter-ginsberg-as-executive-vice-president-corporate-development-chief-business-officer/2478647/The Foundation Fighting Blindness announced the appointment of Peter Ginsberg as executive vice president, corporate development, chief business officer. Mr. Ginsberg will oversee the development of financial plans and processes while providing leadership on busines
- NextGen Launches a Dedicated Optometric Workflow in its Fully Integrated Eye Care Platformhttps://modernod.com/news/nextgen-launches-a-dedicated-optometric-workflow-in-its-fully-integrated-eye-care-platform/2478643/NextGen Healthcare announced it has launched a dedicated optometric workflow in its fully integrated eye care platform. This new optometric software solution is part of the NextGen Ophthalmic Suite, which integrates b
- SIFI Appoints Jelle Kleijn to Lead Effort to Deliver First Registered Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-appoints-jelle-kleijn-to-lead-effort-to-deliver-first-registered-treatment-of-acanthamoeba-keratitis/2478631/SIFI has announced the recent appointment of Jelle Kleijn, PhD, as Global Head of Acanthamoeba keratitis. Dr. Kleijn will lead the efforts aimed at developing and making polihexanide monotherapy available to Acanthamoeba keratitis (AK) patients. Given the urgency to effectively treat AK to
- Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies in Ophthalmic Diseaseshttps://modernod.com/news/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-in-ophthalmic-diseases/2478632/Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Broadwing Bio will advance programs directed to genetically validated ophthalmology targets identified using Maze’s human genetics and
- InMed Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoidshttps://modernod.com/news/inmed-licenses-midrops-delivery-technology-from-eyecro-for-the-delivery-of-therapeutic-cannabinoids/2478621/InMed Pharmaceuticals announced that it has secured an exclusive, worldwide license from EyeCRO for its Microemulsion Drug Ocular Penetration System (MiDROPS) eyedrop delivery technology targeting effective, topical administration of cannabinoids to the eye. EyeCRO is a contract research o